Immunological characteristics of amniotic epithelium
Immunological characteristics of amniotic epithelium
复制标题
DOI：
10.1097/01.ico.0000247214.31757.5c
复制
发表时间：
2006-12-01
期刊：
影响因子：
2.8
通讯作者：
Sakuragawa, Norio
中科院分区：
文献类型：
--
作者：
Hori, Junko;Wang, Mingcong;Sakuragawa, Norio
我们回顾了羊膜上皮细胞免疫抑制和免疫原性潜力的最新实验证据。自冻存羊膜应用于临床以来，许多研究都集中在羊膜基质的有益作用，而不是活羊膜细胞的功能。然而，活的人羊膜上皮细胞（HAECs）已被证明对抗炎因子的分泌产生有益作用。HAECs培养上清液的局部应用可显著抑制角膜中缝线诱导的新生血管形成，并减少热烧灼后发炎角膜中的主要组织相容性复合体（MHC）II类+抗原呈递细胞（APC）。此外，白细胞介素（IL）-1 β mRNA的表达被抑制在烧灼角膜。这些结果表明，HAECs是抑制角膜炎症的可溶性抗炎因子的来源。然而，活的羊膜上皮细胞显示抗原性和免疫原性作为同种异体移植物。新鲜的同种异体羊膜上皮（AE）表达MHC I类抗原，并致敏受体时，放置在眼睛，虽然长期记忆的同种特异性迟发型超敏反应（DH）是不收购。在特异致敏受者和重复AE移植受者中，同种异体AE明显易受急性免疫排斥反应的影响。因此，我们建议不应忽视AE的免疫原性，临床上需要重复AM移植时，应强调使用来自不同供体胎盘的AM。
We review recent experimental evidence of the immunosuppressive and immunogenic potential of amniotic epithelial cells. Since cryopreserved amniotic membrane (AM) has been used in clinical applications,, much research has focused on the beneficial effects of amniotic stromal matrix rather than on the function of viable amniotic cells. However, viable human amniotic epithelial cells (HAECs) have been shown to elicit beneficial effects on secretion of anti-inflammatory factors. Topical application Of Culture supernatant from HAECs leads to profound suppression of suture-induced neovascularization in cornea and fewer major histocompatibility complex (MHC) class II+ antigen-presenting cells (APCs) in inflamed cornea after thermal cautery. Furthermore, expression of interleukin (IL)-1 beta mRNA was suppressed in cauterized cornea. These results suggest that HAECs are a source of Soluble anti-inflammatory factors that suppress corneal inflammation. However, viable amniotic epithelial cells display antigenicity and immunogenicity as allografts. Fresh allogeneic amniotic epithelium (AE) expresses MHC class I antigens and sensitizes recipients when placed in the eye, although long-term memory of allo-specific delayed hypersensitivity (DH) was not acquired. Allogeneic AE was clearly vulnerable to acute immune rejection in specifically sensitized recipients and recipients of repeated AE transplantation. We therefore suggest that immunogenicity of AE should not be ignored, and use of AM from different donor placentas should be emphasized when repeated AM transplantation is required in patients clinically.